Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –
Novartis Scemblix by Quarter
Scemblix — First-Line New Prescription (1L CML NBRx) Market Share in Germany (%)
Novartis Scemblix: 33.0% in Q3 2026.
Latest, Q3 2026
33.0%
Period ended Sep 30, 2026
Change on a year earlier
–
History
3 quarters
Since Q1 2026
Sources
3
Documents cited below
Where the Q3 2026 figure comes from
“| 233 | 18 | 27 | 19 | achieving 56% share, DE 1L NBRx | 15 | share 33%5”
Source: Novartis Official IR / Sustainability Report — q3-2026-investor-presentation.pdf ↗
Reported in Quarterly Investor Presentations.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Scemblix — First-Line New Prescription (1L CML NBRx) Market Share in Germany (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 33.0% | – | Novartis Official IR / Sustainability Report — q3-2026-investor-presentation.pdf ↗ |
| Q2 2026 | Jun 30, 2026 | 15.0% | – | Novartis Official IR / Sustainability Report — q2-2026-investor-presentation.pdf ↗ |
| Q1 2026 | Mar 31, 2026 | 11.0% | – | Novartis Official IR / Sustainability Report — q1-2026-investor-presentation.pdf ↗ |
Cite this data
StockData. (2026). Novartis Scemblix (%), quarterly Q1 2026–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/rx-scemblix-de-1l-nbrx-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.